Drug intelligence / Profile preview

TPST-001

Development stage: Preclinical
Lead developer: Tempest Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

TPST-001 is a preclinical, in vivo chimeric antigen receptor (CAR) T-cell therapy being developed by Tempest Therapeutics for the treatment of non-B-cell hematologic malignancies. It is built on Tempest's proprietary CD7-targeted lipid nanoparticle (CD7-tLNP) platform, which is designed to deliver nucleoside-modified mRNA directly to both CD4+ and CD8+ T cells within the body. This in vivo approach bypasses the need for ex vivo cell collection, engineering, and reinfusion, aiming to improve manufacturing scalability, reduce production costs, and enable broader T-cell engagement and repeat dosing.

Targets

CD7 (CD7 antigen)

Beyond the preview

Go deeper on TPST-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TPST-001.